Ng et al.68 and colleagues tested the activity of the mTOR inhibitor Everolimus in mice transplanted with the CD4-RhoAG17VTet2−/−; OT-II tumors with a strong reduction of tumor burden as a result and increased survival of the mice (Fig. 4c). This evidence concerns the gene CD4 and neoplasm.